Bionime (TPE:4737) Cyclically Adjusted PS Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4737 Bionime Corp TPE:4737
69 GF Score
Price NT$55.00
GF Value NT$56.45
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Bionime Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bionime  (TPE:4737) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Bionime Cyclically Adjusted PS Ratio Related Terms


Bionime Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Bionime's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionime Cyclically Adjusted PS Ratio Chart

Bionime Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.09 2.02 1.98 1.73 1.76

Bionime Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.64 1.91 1.84 1.76 1.99

TPE:4737 vs ISRG, BDX, MDLN: Cyclically Adjusted PS Ratio Comparison

For the Medical Instruments & Supplies subindustry, Bionime's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionime Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionime's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bionime's Cyclically Adjusted PS Ratio falls into.


TPE:4737
69GF Score
Bionime Corp TPE:4737
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionime Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Bionime's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Bionime's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=5.527/330.2130*330.2130
=5.527

Current CPI (Mar. 2026) = 330.2130.

Bionime Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 6.134 241.018 8.404
201609 6.279 241.428 8.588
201612 7.394 241.432 10.113
201703 5.438 243.801 7.365
201706 6.374 244.955 8.593
201709 6.758 246.819 9.041
201712 8.925 246.524 11.955
201803 6.012 249.554 7.955
201806 6.849 251.989 8.975
201809 8.706 252.439 11.388
201812 9.566 251.233 12.573
201903 5.678 254.202 7.376
201906 8.853 256.143 11.413
201909 7.539 256.759 9.696
201912 10.951 256.974 14.072
202003 5.445 258.115 6.966
202006 5.665 257.797 7.256
202009 6.691 260.280 8.489
202012 7.539 260.474 9.557
202103 6.848 264.877 8.537
202106 6.174 271.696 7.504
202109 7.300 274.310 8.788
202112 7.137 278.802 8.453
202203 7.022 287.504 8.065
202206 8.418 296.311 9.381
202209 8.394 296.808 9.339
202212 8.702 296.797 9.682
202303 6.159 301.836 6.738
202306 6.189 305.109 6.698
202309 6.432 307.789 6.901
202312 7.022 306.746 7.559
202403 6.930 312.332 7.327
202406 7.042 314.175 7.401
202409 7.186 315.301 7.526
202412 7.409 315.605 7.752
202503 7.279 319.799 7.516
202506 6.909 322.561 7.073
202509 6.754 324.800 6.867
202512 6.288 324.054 6.408
202603 5.527 330.213 5.527

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Bionime (TPE:4737) Overvalued in 2026?

Based on GuruFocus' analysis, Bionime stock appears to be undervalued. The current stock price of NT$55.00 is trading 2.6% below its estimated GF Value™ of NT$56.45. GuruFocus considers Bionime to be Fairly Valued.

Key valuation signals for TPE:4737:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: NT$56.45 vs. price of NT$55.00 (2.6% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bionime Business Description

Address No. 100, Daqing Street, Section 2, South District, Taichung, TWN, 40242
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
69GF Score

Get the complete analysis for TPE:4737

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$55.00
Price
NT$56.45
GF Value